Top Ten most popular articles on Pharmafile.com this week
Friday again, and we bring you the most read articles on our site this week – one of which was the startling news that 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or more.
Recent staff rumblings at GSK proved to be very popular with our readers this week, as news emerged that GSK’s Head of R&D is to leave the company to become the UK Government’s Chief Scientific Adviser. In addition, the company has also welcomed Hal Barron as its Chief Scientific Officer and President of R&D, awarding him a position on the board of the company.
The most popular piece this week, however, was our in-depth feature on the exciting world of CAR-T therapy, and how recent approvals could mean big things for the future of cancer treatment.
Check out the week’s ten most popular articles on Pharmafile.com now!
A young child has been brought back from the verge of death after an experimental combination of stem cell and gene therapy procedures managed to repair his badly damaged skin.
At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or more, according to new data revealed by Macmillan Cancer Support and Public Health England’s (PHE) National Cancer Registration and Analysis Service.
The UK government has announced its response to the Accelerated Access Review that was published last year, with former GSK CEO tasked to lead a panel in proposing a handful of drugs and devices to be sped through the system.
Merck KGaA released results of its osteoarthritis treatment that could become the first treatment to successfully slow or halt the disease.
NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both multiple sclerosis and breast cancer, it has emerged.
Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma (DLBCL) for its CAR-T treatment, Kymriah, now the company has gone to the EMA hoping to secure two indications at the same time.
Transparency is becoming important across a whole range of industries but, for the pharmaceutical industry, it can mean life or death. Ben Hargreaves examines the push for more clinical trial data to be revealed so that research can continue to move forward and to stop unfavourable results becoming lost.
There has been a raft of changes at senior levels of GSK since Emma Walmsley took over the role from Andrew Witty, with the latest seeing its R&D head set to leave to become the UK government’s Chief Scientific Adviser.
GSK, under its new CEO, has made most of its waves recently not with approvals but with high-profile appointments, and it continued in this trend with the appointment Hal Barron.
Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment is changed forever.
COVID-19 news has slowed down in the last week, allowing different pharma developments to take …
As the year winds to a close, excitement is rising around the efficacy and availability …